Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELVN vs LGND: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LGND Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

LGND Overall Winner 6-Pillar Tally: ELVN 1 – 5 LGND Matrix Metrics: ELVN 1 – 9 LGND

As of Nov 16, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas LGND carries 42.6/100 (HOLD) at $304.93 (25.8x Forward P/E, 14.4% operating margin).

  • Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. ELVN 36.2/100 SELL) and 0.99β · 38% Vol risk profile, whereas ELVN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELVN vs LGND
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.2 · SMA20: $45.77 · SMA50: $46.19
LGND NASDAQ Head-to-Head Winner
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$304.93
-1.25% 1D
Market Cap $6.3B
TTM Revenue $254M
Forward P/E 25.8x
Beta / 30D Vol 0.99β · 38% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 44.0 Fund 47.0 Flow 63.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.6 · SMA20: $311.42 · SMA50: $302.10

6-Pillar Scorecard Institutional Category Breakdown (ELVN 1 – 5 LGND)

Columns: Metric · ELVN · LGND
1. Valuation Multiples LGND
Forward P/E N/M 25.8x
Trailing P/E N/M 127.0x
PEG Ratio N/M 1.53x
EV / Revenue N/M 29.3x
2. Growth & Scale LGND
Revenue Growth (YoY) +0.0% -31.8%
Earnings Growth (YoY) +0.0% +825.0%
TTM Revenue (USD) N/A $254M
Market Cap $3.6B $6.3B
3. Profitability & Quality LGND
Gross Margin N/A 86.1%
Operating Margin 0.0% 14.4%
Net Profit Margin 0.0% 20.3%
Return on Equity (ROE) -16.8% 5.4%
4. Balance Sheet & Cash Flow LGND
Cash Generation (TTM) -$66M $57M
Cash Flow Margin N/A 22.6%
Net Cash / Leverage $150M Net Cash $1.10B Net Debt (1.20x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ELVN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 46.9% (5th %ile) 37.9% (8th %ile)
Put/Call OI Skew 1.67x (Put-Skewed) 0.42x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat LGND
OpEx & R&D Intensity N/A 71.7% of Rev ($182M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELVN (1) vs LGND (9)
Institutional Metric ELVN LGND Criterion Row Edge
Market Capitalization
Scale
$3.6B $6.3B Larger Scale LGND
Trailing P/E Ratio
Valuation
N/M 127.0x Lower Multiple LGND
Forward P/E Ratio
Valuation
N/M 25.8x Lower Multiple LGND
Revenue Growth (YoY)
Growth
+0.0% -31.8% Higher Growth ELVN
Operating Margin (TTM)
Profitability
0.0% 14.4% Higher Margin LGND
Net Profit Margin
Profitability
0.0% 20.3% Higher Margin LGND
Return on Equity (ROE)
Capital Efficiency
-16.8% 5.4% Higher ROE LGND
52-Week Range Position
Momentum
69% ($15–$62) 86% ($176–$327) Stronger Trend LGND
Beta / 30D Volatility
Risk Regime
0.96β · 60% Vol 0.99β · 38% Vol Lower Realized Risk LGND
Unified Institutional Score
Composite Signal
36.2 / 100 (SELL) 42.6 / 100 (HOLD) Higher Composite LGND
Trailing 12M Revenue (USD)
Operating Scale
N/A $254M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 86.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.53x PEG · 29.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($150M Net Cash) $57M ($1.10B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +24.2 pp
ELVN: +27.38% · LGND: +3.18%
3M Horizon LGND +26.89 pp
ELVN: -20.86% · LGND: +6.03%
6M Horizon LGND +26.72 pp
ELVN: +19.96% · LGND: +46.68%
1Y Horizon ELVN +83.03 pp
ELVN: +134.53% · LGND: +51.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs LGND. Trailing 12-month operating profitability (ELVN 0.0% vs LGND 14.4%) and valuation multiples (ELVN N/M vs LGND 25.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M
LGND ADR TTM Benchmark FX-Normalized USD
TTM Revenue$254M
Gross Margin86.1%
Op. Margin14.4%
ROE / Fwd P/E5.4% · 25.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LGND CONSOLIDATION
98d in phase · OBV NEUTRAL
Current IV 37.9%
IV Percentile 8th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LGND Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LGND Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment 71.7% of Rev ($182M)
90D Engineering Disclosures 0 Published

Investor FAQ ELVN vs LGND Key Questions & Quantitative Answers

As of Nov 16, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas LGND carries 42.6/100 (HOLD) at $304.93 (25.8x Forward P/E, 14.4% operating margin). Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. ELVN 36.2/100 SELL) and 0.99β · 38% Vol risk profile, whereas ELVN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

LGND leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LGND at -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $254M for LGND. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus 71.7% of Rev ($182M) (0 disclosures) for LGND.

LGND screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LGND trades at 25.8x Forward P/E, 127.0x Trailing P/E, 1.53x PEG, and 29.3x EV/Revenue (22.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus LGND (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, LGND carries 37.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.99β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.